Ozempic: The Drug Threatening the Alcohol Industry

A clinical trial published in The Lancet in 2026 has shown that semaglutide, the active ingredient in Ozempic and Wegovy, significantly reduces alcohol consumption in people with alcohol use disorder. The study, with 108 participants over 26 weeks, showed a 41.1% reduction in heavy drinking days compared to 26.4% with placebo. This finding adds to previous research suggesting that GLP-1 agonists could help treat addictions. A phase 2 study published in 2025 in JAMA Psychiatry had already shown similar results in a smaller cohort of 48 patients, with a 35% reduction in alcohol consumption. The consistency between both studies reinforces the hypothesis that these drugs modulate the brain's reward system, decreasing the desire for addictive substances such as alcohol, nicotine, and food.

Why is this important?

Ozempic has become a global social phenomenon due to its effectiveness for weight loss, leading millions of people to use it. According to IQVIA data, in 2025 over 50 million prescriptions for GLP-1 agonists were issued in the United States, 40% more than the previous year. If these patients also reduce their alcohol intake, the cumulative impact on the alcohol industry could be massive. The industry already faces a decline in consumption among young people, who are increasingly opting for abstinence. A 2025 Gallup report indicates that 39% of adults aged 18 to 34 identify as abstainers, up from 28% in 2015. Ozempic could accelerate this trend, affecting sales of beer, wine, and spirits. Moreover, the effect is not limited to alcohol: observational studies have reported reductions in tobacco use, gambling, and compulsive shopping, suggesting a broader impact on consumption habits.

Consequences for the alcohol industry

Companies in the sector will need to adapt to a consumer who drinks less and less frequently. This could translate into a decline in revenue, especially in categories like beer and spirits. On the other hand, an opportunity could arise for non-alcoholic or low-alcohol beverages, as well as products aligned with a healthy lifestyle. Stocks of companies like Diageo or Anheuser-Busch InBev could face pressure if the trend consolidates. In fact, in 2025, Constellation Brands' shares fell 8% after the first study on semaglutide and alcohol was published, though they later partially recovered. A 2026 Morgan Stanley analysis estimates that if 10% of U.S. adults use GLP-1 agonists by 2030, per capita alcohol consumption could decrease by 2% to 5%, representing a revenue loss of up to $15 billion for the industry.

What should readers know?

• Ozempic's effect on alcohol is not an isolated side effect: it is part of a mechanism that reduces the desire for pleasurable substances, including food and alcohol. GLP-1 agonists act on receptors in the brain that regulate reward and motivation, decreasing dopamine release in response to addictive stimuli.
• Although the results are promising, it is not yet approved for treating alcohol use disorder. More long-term studies are needed, with larger and more diverse samples, and to assess potential adverse effects such as nausea, vomiting, or pancreatitis. The U.S. Food and Drug Administration (FDA) has not yet issued an official statement, but phase 3 trials are expected to begin in 2027.
• The popularity of Ozempic for weight loss has led to increased off-label use, which could raise the number of people experiencing this effect. However, the drug's high cost (about $1,000 per month without insurance) and supply issues limit its widespread access. Additionally, the emergence of generic versions of semaglutide by 2028 could democratize its use.

Historical context

This is not the first time a drug has revolutionized consumption habits. For example, the arrival of SSRI antidepressants in the 1990s changed the social perception of mental health. Ozempic could have a similar impact on the relationship with food and alcohol. Moreover, the alcohol industry has already survived crises like Prohibition in the U.S. or campaigns against drunk driving. However, the combination of a mass-market drug and a cultural shift toward abstinence could be unprecedented. Historically, reductions in alcohol consumption have been associated with economic factors (recessions), regulatory measures (tax increases), or cultural movements (health trends). Ozempic introduces a biological-pharmacological factor that could accelerate the trend independently. For instance, in Japan, where alcohol consumption has fallen 30% in the last decade due to demographic and lifestyle changes, the introduction of GLP-1 agonists could further deepen the decline.

“People who took semaglutide reduced heavy drinking days by 41.1% compared to 26.4% for those who took placebo.” — The Lancet, 2026

In conclusion, Ozempic is not only transforming the treatment of diabetes and obesity but could also reshape the alcohol industry. Investors and industry executives should closely monitor these developments and prepare for a scenario of lower per capita consumption. Companies that diversify into non-alcoholic alternatives or invest in health-aligned products could mitigate the impact. Meanwhile, the scientific community continues to explore the potential of GLP-1 agonists to treat addictions, which could open a new therapeutic avenue with profound social and economic implications.